Although IFN-α is effective in achieving control of CML in most patients, the resistance of CML to IFN-α might emerge de novo or during treatment and ultimately leads to disease progression [16]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.